Intraperitoneal Atomization of Levobupivacaine During Gynaecological Laparoscopic Procedures ; Impact on Pain, Opioid Use and Length of Recovery Room Stay (IPLA). (IPLA)
Pain, Postoperative
About this trial
This is an interventional treatment trial for Pain, Postoperative focused on measuring laparoscopic, pain
Eligibility Criteria
Inclusion Criteria:
- Patients who are planned for gynaecological laparoscopic interventions on an ambulatory basis.
Exclusion Criteria:
- Less than 18 year old.
- Weight less than 50 kg and more than 80 kg.
- Pregnant.
- Prisoners;
- Allergic to topical anesthetics (Amides specifically).
- Allergic to Opioids as a class.
- Currently or within the last 30 days been prescribed an opiate medication.
- Chronic pain syndrome.
Sites / Locations
- Ghent University Hospital
Arms of the Study
Arm 1
Arm 2
Arm 3
Active Comparator
Experimental
Experimental
Infiltration of portal sites with 0,5% levobupivacaine.
Additional injection of 0.5% levobupivacaine via a trocar
Additional intraperitoneal atomization of levobupivacaine.
The first group of patients will receive the standard treatment (paracetamol, diclofenac and an opioid if necessary) with infiltration of the portal sites with the local anesthetic ( 0.5% levobupivacaine).
The second group of patients will receive the standard of care, with infiltration of the portal sites with the local anesthetic ( 0.5% levobupivacaine) and additional injection of the local anesthetic ( 0.5% levobupivacaine, non -diluted) in the peritoneal cavity via a trocar both at the beginning and the end of the surgery.
The third group of patients will receive the standard of care, with infiltration of the portal sites with the local anesthetic ( 0.5% levobupivacaine) and additional intraperitoneal atomization of the local anesthetic.